AG-NIFEDIPINE ER TABLET (EXTENDED-RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

NIFEDIPINE

متاح من:

ANGITA PHARMA INC.

ATC رمز:

C08CA05

INN (الاسم الدولي):

NIFEDIPINE

جرعة:

60MG

الشكل الصيدلاني:

TABLET (EXTENDED-RELEASE)

تركيب:

NIFEDIPINE 60MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

15G/50G

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

DIHYDROPYRIDINES

ملخص المنتج:

Active ingredient group (AIG) number: 0115253005; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2021-01-27

خصائص المنتج

AG-Nifedipine ER
1
PRODUCT MONOGRAPH
PR
AG-NIFEDIPINE ER
Nifedipine Extended Release Tablets USP
60 mg
Antianginal/Antihypertensive Agent
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Québec
J4B 5H3
Date of Revision:
January 21, 2021
Submission Control No.: 247279
AG-Nifedipine ER
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSION-AL INFORMATION
................................................................ 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
.................................................................................................................
8
DRUG INTERACTIONS
...............................................................................................................
12
DOSAGE AND ADMINISTRATION
...........................................................................................
17
OVERDOSAGE
..............................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
18
STORAGE AND STABILITY
.......................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 21
PART II: SCIENTIFIC INFORMATION
.......................................................................................
23
PHARMACEUTICAL INFORMATION
.....................................................................................
23
CLINICAL TRIALS
......................